Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 7996 AL 8010

Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities

Cogswell PM, Andrews TJ, Barakos JA, Barkhof F, Bash S, Benayoun MD, Chiang GC, Franceschi AM, Jack CR Jr, Pillai JJ, Poussaint TY, Raji CA, Ramanan VK, Tanabe J, Tanenbaum L, Whitlow CT, Yu FF, Zaharchuk G, Zeinah M, Benzinger TS; ASNR Alzheimer, ARIA, and Dementia Study Group.

AJNR Am J Neuroradiol. 2025 Jan 8;46(1):24-32. doi: 10.3174/ajnr.A8469.

Impact of Mouthwash-Induced Oral Microbiome Disruption on Alzheimer's Disease Risk: A Perspective Review

Boulares A, Jdidi H, Bragazzi NL.

Int Dent J. 2025 Feb;75(1):45-50. doi: 10.1016/j.identj.2024.07.005. Epub 2024 Oct 8.

[Epileptic seizures in patients with Alzheimer's disease]

Burd SG, Bogolepova AN, Lebedeva AV, Rubleva YV, Kovalenko EA, Makhnovich EV, Osinovskaya NA, Gileva EA, Pantina NV, Kovaleva II, Efimenko AP, Bokitko TA, Alekseeva GA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(11):36-43. doi: 10.17116/jnevro202512511136.

Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective

Scarano N, Musumeci F, Casini B, Brullo C, D'Ursi P, Fossa P, Schenone S, Cichero E.

Int J Mol Sci. 2025 Jul 20;26(14):6980. doi: 10.3390/ijms26146980.

Is US residence a risk factor for Alzheimer's disease?

Høilund-Carlsen PF, Alavi A, Costa T, Neve RL, Perry G, Revheim ME, Barrio JR.

J Alzheimers Dis. 2025 Sep;107(2):496-498. doi: 10.1177/13872877251356682. Epub 2025 Sep 1.

Use of Drugs Affecting GABA(A) Receptors and the Risk of Developing Alzheimer's Disease and Dementia: a Meta-Analysis and Literature Review

Vakili K, Fathi M, Ebrahimi R, Ahmadian S, Moafi M, Ebrahimi MJ, Tafazolimoghadam A, Davoodi A, Eghbaldoost A, Eyvani K, Ghayyem H, Jashni Pour M, Kosari M, Niknejad S, Sanaye Abbasi A, Zarebidoki A, Andrew M, Trenaman S, Batool Z, Sayehmiri F, Ebrahimzadeh K.

Mol Neurobiol. 2025 Jul;62(7):9449-9468. doi: 10.1007/s12035-025-04821-9. Epub 2025 Mar 20.

Red blood cell ω-3 status and longitudinal cognition in individuals at risk of Alzheimer disease

Lázaro I, Brugulat-Serrat A, Suárez-Calvet M, Fauria K, Minguillon C, Gispert JD, Molinuevo JL, Harris WS, Sánchez-Benavides G, Grau-Rivera O, Sala-Vila A; ALFA study.

J Nutr. 2025 Dec;155(12):4514-4522. doi: 10.1016/j.tjnut.2025.09.032. Epub 2025 Sep 27.

Brexpiprazole: A Balance of Risks and Benefits

Hitt EM.

Sr Care Pharm. 2025 Mar 1;40(3):115-122. doi: 10.4140/TCP.n.2025.115.

Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer's Disease

Imbimbo C, Cotta Ramusino M, Leone S, Mazzacane F, De Franco V, Gatti A, Perini G, Costa A.

CNS Drugs. 2025 Feb;39(2):143-160. doi: 10.1007/s40263-024-01133-9. Epub 2024 Dec 2.

Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome

Dohl J, Treadwell Z, Norris C, Head E.

Alzheimers Dement. 2025 Mar;21(3):e70034. doi: 10.1002/alz.70034.

Effect of Alzheimer's disease medications on neurocognitive outcomes in children and adolescents with autism spectrum disorder and low IQ: a scoping review

Diamandis N, van den Anker JN, Denisova K.

Transl Psychiatry. 2025 Nov 17;15(1):475. doi: 10.1038/s41398-025-03655-2.

Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers

Barroeta I, Videla L, Carmona-Iragui M, Fortea J, Rafii MS.

Alzheimers Dement. 2025 Jun;21(6):e70258. doi: 10.1002/alz.70258.

Current and Emerging Pharmacological Approaches to Agitation in Alzheimer's Disease: A Narrative Review of New and Repurposed Therapies

Smoller C, Schiller E, Yamashita K, Silverglate BD, Grossberg GT.

Drugs. 2025 Nov;85(11):1391-1411. doi: 10.1007/s40265-025-02227-4. Epub 2025 Sep 6.

A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease

Zhong K, Cummings J.

Expert Rev Neurother. 2025 Jan;25(1):5-13. doi: 10.1080/14737175.2024.2407836. Epub 2024 Sep 29.

A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel

Grossberg GT, Sanford A, Montano CB, Porsteinsson AP, Scanland S, Worz C, McMillian S, Atri A.

Postgrad Med. 2025 Aug;137(6):469-485. doi: 10.1080/00325481.2025.2517535. Epub 2025 Jun 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias